pALD Lenti Products

Lentiviral vector plasmids

A solution from early research through commercial development

Aldevron provides pALD Lenti packaging plasmids through our partnership with OXGENE, who have optimized them for lentiviral vector production. They are immediately available at research grade, GMP-Source, and for custom GMP productions. This reduces your costs and significantly reduces time to manufacture vectors for clinical trials.

The Aldevron pALD-Lenti system has several advantages:

  • Immediately available at Research Grade and GMP-Source®
  • Royalty free
  • Demonstrated performance producing high-quality lentiviral vectors

Provided under license from: oxgene-logo

Cell Therapy with Lentivirus

pALD-Lenti System

What's included

We provide three packaging plasmids and an expression plasmid, including: Common to all rLenti production

  • pALD-Lenti
  • pALD-VSV-G
  • pALD-GagPol
  • pALD-Rev

We can clone your gene of interest into the pALD-Lenti expression plasmid, replacing the EGFP sequence. 

The system has been optimized and represents the state of the art in lentiviral vector production, including:

  • Codon optimizationLentiviral Vector
  • Vector backbones minimized
  • Minimization of homology with HIV/VSV
  • Minimization of inter-cassette homology
In addition to the optimized design, lentiviral vectors produced with pALD Lenti transfect cells at a higher rate than commercially available kits with infectious titers in the range of 5 x 107/ml. 

Note: pALD-VSV-G products are classified by Aldevron under 1C353 on the Commerce Control List set forth in the US Export Administration Regulations (EAR), which is highly controlled for purposes of export outside the United States. If the product is requested to be shipped outside the US, an export license from US Dept. of Commerce’s Bureau of Industry and Security is required before the product may be shipped.

pALD-Lenti Plasmid Maps









pALD-Lenti Quality Control Specifications

Appearance Clear and Colorless
Buffer TE
USP Sterility <71> * No Growth
Concentration 1.0 mg/mL +/- 10%
DNA Homogeneity ≥ 80% Supercoiled
Endotoxin ≤ 100 EU/mg
Identity Confirmed Against DNA Ladder
Plasmid Identity Identical to Reference Sequence
ABS 260/280 Ratio Purity 1.80 - 2.00
Residual Host Genomic DNA via qPCR ≤ 5%
Residual Host Protein via BCA ≤ 2%
Residual Host RNA via SYBR Gold ≤ 5% by Semi-Quantitative Densitometry
Restriction Digest Matches Expected Restriction Pattern
Mycoplasma Contamination Negative for the Presence of Mycoplasma

*Sterility testing is not available for research grade material. Bioburden by direct inoculation with a specification of no growth after 48 hours is performed at the research grade level.

Request a Complete CoA